Head and Neck Squamous Cell Carcinoma (HNSCC) Market Size & Share, by Drug Class (Immunotherapy, Chemotherapy, Targeted Therapy); Distribution Channel (Hospital Pharmacies, Retail, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2839
  • Published Date: Mar 20, 2023
  • Report Format: PDF, PPT

Companies Dominating the Head and Neck Squamous Cell Carcinoma (HNSCC) Landscape

    • Immutep Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Fortress Biotech, Inc.
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Bristol Myers Squibb Company
    • AstraZeneca PLC
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Checkpoint Therapeutics, Inc.


In The News

  • Immutep Limited announced that it has completed the recruitment of patients having head and neck cancer and has safely dosed them for stage 2 of Part C of its Two ACTive Immunotherapies (TACTI-002) Phase II study trials.

  • Checkpoint Therapeutics, Inc. announced that it has expanded its partnership with Samsung Biologics Co., Ltd. for manufacturing the anti-PD-L1 antibody, cosibelimab on a commercial scale.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2839
  • Published Date: Mar 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing R&D and approvals for cancer drugs and treatment, escalating consumption of alcohol, and growing adoption of immune therapeutics are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2035.

High cost of head & neck cancer treatment and drugs, and adverse effects of concerned drugs are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Immutep Limited, Novartis AG, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca PLC, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, distribution channel, and by region.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying